原标题:康方生物-B(09926.HK):Cadonilimab (PD-1/CTLA-4双特异性抗体)获美 来源:智通财经智通财经APP讯,康方生物-B(09926.HK)公布,该公司核心自主研发的、全球首创的新型肿瘤免疫治疗双特异性抗体新药Cadonilimab(PD-1/CTLA-4双特异性抗体,研发代号: AK104)获得美国食品药品监督管理局(“FDA”)授予的孤儿药资格认定,用于治疗...
Source Link原标题:康方生物-B(09926.HK):Cadonilimab (PD-1/CTLA-4双特异性抗体)获美 来源:智通财经智通财经APP讯,康方生物-B(09926.HK)公布,该公司核心自主研发的、全球首创的新型肿瘤免疫治疗双特异性抗体新药Cadonilimab(PD-1/CTLA-4双特异性抗体,研发代号: AK104)获得美国食品药品监督管理局(“FDA”)授予的孤儿药资格认定,用于治疗...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.